Sarcopenia is associated with decreased gray matter volume in the parietal lobe: a longitudinal cohort study

Ji Hee Yu1†, Regina E. Y. Kim2,3†, Jin-Man Jung4, So Young Park1, Da Young Lee1, Hyun Joo Cho1, Nam Hoon Kim1, Hye Jin Yoo1, Ji A Seo1, Sin Gon Kim1, Kyung Mook Choi1, Sei Hyun Baik1, Chol Shin2*† and Nan Hee Kim1*†

Abstract
Background: Substantial evidence supports an association between physical activity and cognitive function. However, the role of muscle mass and function in brain structural changes is not well known. This study investigated whether sarcopenia, defined as low muscle mass and strength, accelerates brain volume atrophy.

Methods: A total of 1284 participants with sarcopenic measurements and baseline and 4-year follow-up brain magnetic resonance images were recruited from the Korean Genome and Epidemiology Study. Muscle mass was represented as appendicular skeletal muscle mass divided by the body mass index. Muscle function was measured by handgrip strength. The low mass and strength groups were defined as being in the lowest quintile of each variable for one’s sex. Sarcopenia was defined as being in the lowest quintile for both muscle mass and handgrip strength.

Results: Of the 1284 participants, 12.6%, 10.8%, and 5.4% were classified as the low mass, low strength, and sarcopenia groups, respectively. The adjusted mean changes of gray matter (GM) volume during 4-year follow-up period were −9.6 mL in the control group, whereas −11.6 mL in the other three groups (P < 0.001). The significantly greater atrophy in parietal GM was observed in the sarcopenia group compared with the control group. In a joint regression model, low muscle mass, but not muscle strength, was an independent factor associated with a decrease of GM volume.

Conclusions: Sarcopenia is associated with parietal GM volume atrophy, in a middle-aged population. Maintaining good levels of muscle mass could be important for brain health in later adulthood.

Keywords: Sarcopenia, Skeletal muscle, Muscle strength, Brain atrophy, Gray matter
disability and various adverse health outcomes, including falls, fractures, and mortality [2].

Substantial evidence from cross-sectional studies shows an association between muscle function and brain function [3, 4] or structure [5–8]. A positive correlation was found between gait speed and total brain volume [5, 6], but no significant link has been reported between handgrip strength and total brain volume, except for some positive associations with white matter (WM) volume [7, 8]. On the other hand, few studies have examined the relationship between muscle mass and brain structure. Burns et al. reported that lean mass was positively associated with total brain volume in participants with early Alzheimer’s disease and controls without dementia, and that association was largely driven by WM volume [9]. Total gray matter (GM) volume was not associated with lean mass except in some regional areas [9, 10]. However, those were mostly cross-sectional studies with a small number of participants. No large-scale, longitudinal study has evaluated the association between brain structure and skeletal muscle mass indices that combine muscle mass and function, as suggested by guidelines from sarcopenia working groups.

In this study, we investigated whether sarcopenia, defined as low muscle mass and strength together, is associated with brain volume atrophy in a middle-aged population, along with the independent effects of low muscle mass and function on brain volume reduction.

Methods
Participants
All study subjects were taken from the Ansan cohort of the Korean Genome Epidemiology Study (KoGES), an ongoing population-based cohort study that began in 2001. KoGES participants have been biennially evaluated for demographics, medical illness, and medications. During the 6th and 7th examination cycles (2011–2014), brain magnetic resonance imaging (MRI) scans and handgrip strength data were acquired. Four years later, follow-up brain MRI scans were conducted during the 8th and 9th exams (2015–2018). Further details are described elsewhere [11].

In this study, we included 1905 subjects who completed baseline dual-energy X-ray absorptiometry (DEXA) with their handgrip strength tests and had baseline and follow-up brain MRI scans. The DEXA exams were performed from the 5th examination cycle (2009–2010). We excluded 621 subjects with the following conditions: 1) past history of dementia (n = 1), 2) any neuropsychiatric disorders, including anxiety, mood, or psychotic disorders (n = 6), 3) stroke (n = 29), 4) any cancer (n = 21), 5) diabetes mellitus (n = 553), 6) missing data (n = 11). After those exclusions, 1284 participants were enrolled in this study. Each participant signed an informed consent form. This study was performed according to the principles of the Declaration of Helsinki of the World Medical Association and was approved by the Institutional Review Board of Korea University Ansan Hospital.

Assessments
Demographic, anthropometric, and laboratory measurements
All participants underwent physical examinations and responded to an interviewer-administered questionnaire that included physical activity-related questions. “Do you work out regularly enough to make your body sweat? How many times a week, how many hours, and what kind of exercise do you do?” was designated to determine the frequency, time and type of self-reported exercises. Regular exercise was defined as at least three times a week and 30 min per session during the previous month regardless of type of exercise. No participants have been involved in exercise-related interventions. Lifestyle characteristics, such as smoking status and alcohol consumption, were categorized as never, former, and current. Education level was categorized into primary, secondary, and college/university levels. Height was measured to the nearest 0.1 cm using a fixed wall-scale measuring device. Weight was measured to the nearest 0.1 kg using an electronic scale that was calibrated before each measurement. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured to the nearest 0.5 cm in a horizontal plane at the level of the umbilicus at the end of a normal expiration.

Blood was drawn for biochemical analysis after an overnight fast. Plasma glucose, serum triglycerides, and high-density lipoprotein cholesterol levels were measured with an autoanalyzer (ADVIA 1650; Siemens, Tarrytown, NY). High-sensitive C-reactive protein (hsCRP) levels were measured by an immunoassay (ADVIA1800, Siemens, USA). Insulin was measured with an immunoradiometric assay kit (INS-IRMA Kit; BioSource, Nivelles, Belgium) using a Packard y counter system.

Brain magnetic resonance imaging and z-score calculation
All 3D T1 MRI scans were acquired using a GE Signa HDxt 1.5 T MRI scanner with an 8-channel head coil. The detailed MRI protocols are described in a previous study [11]. Brain MRI images were processed through a well-established fully automated procedure, the BRAINS AutoWorkup in the BRAINSTOOLs package [12, 13]. The MRI processing starts with spatial normalization using landmark detection [14], bias-field correction with tissue classification [13], and finally segmentation using ANTs Joint Fusion [15]. Two hundred fifteen independent brain
subcompartments were automatically delineated, and the volumes were measured. The high reliability of the longitudinal measurement of two-time point MRI using the BRAINS AutoWorkup previously described [11]. The subcompartments were merged into 3 tissue classes: GM, WM, and cerebrospinal fluid. All the volume measurements were extracted from an individual’s original anatomical space. GM and WM volumes were summed to obtain total brain volume.

**Definition of diabetes mellitus, hypertension, heart disease, and sarcopenia**

Diabetes mellitus was diagnosed when the fasting plasma glucose was \( \geq 7.0 \text{ mmol/L} \), 2-h plasma glucose was \( \geq 11.1 \text{ mmol/L} \) after a 75 g oral glucose tolerance test, or participants took anti-diabetic medication [18]. Insulin resistance was estimated using the homeostasis model of assessment for insulin resistance (HOMA-IR), which is calculated as fasting glucose (mmol/L) \times \) fasting insulin (\( \mu U/mL \)) / 22.5 [19]. Hypertension (HTN) was diagnosed when the systolic or diastolic blood pressure was equal to or above 140 or 90 mmHg, respectively, or when the systolic or diastolic blood pressure was equal to or above 140 or 90 mmHg, respectively, or when the systolic or diastolic blood pressure was equal to or above 140 or 90 mmHg, respectively, or when the systolic or diastolic blood pressure was equal to or above 140 or 90 mmHg, respectively.

**Hypertension (HTN)** was diagnosed when the systolic or diastolic blood pressure was \( \geq 140 \) or 90 mmHg, respectively, or when the systolic or diastolic blood pressure was equal to or above 140 or 90 mmHg, respectively.

**Insulin resistance (HOMA-IR)** is calculated as fasting glucose (mmol/L) \( \times \) fasting insulin (\( \mu U/mL \))/22.5 [19].

**Measurement of body composition and handgrip strength**

Whole body composition was determined using DEXA. Total body fat mass (g) and total and regional lean mass (g) were measured using a Lunar DPX-MD densitometer (GE Medical Systems, Madison, WI). Appendicular skeletal muscle mass (ASM, kg) was defined as the sum of the lean soft tissue mass of the arms and legs [16], and BMI-corrected ASM (ASM/BMI) was also calculated [17]. Handgrip strength was measured using a digital strength dynamometer (TKK 5401, Takei, Japan) to evaluate muscle strength. During the assessment, participants were asked to stand upright with their feet hip-width apart and arms extended straight down to the side unless they were physically limited. The dynamometer was held by the testing hand in a neutral (not flexed or extended) and comfortable position. Two trials for each hand were performed with a one-minute rest after each trial, and the values from both hands were averaged for analysis.

**Statistical analysis**

Baseline characteristics were compared among four groups classified by muscle mass and strength using one-way analysis of variance (ANOVA) with the Tukey post hoc test for numeric variables. The chi-square test was used to compare categorical variables. Non-normally distributed variables, such as hemoglobin A1c, triglycerides, HOMA-IR, hsCRP, and handgrip strength, are presented as the median with interquartile range for each group, and differences were tested after logarithmic transformation. The brain volume change was calculated by subtracting the baseline brain volume from the follow-up brain volume. We compared adjusted mean changes in total and regional brain volume according to groups classified by baseline muscle mass and strength using analysis of covariance (ANCOVA) with the Tukey post hoc test. For parietal GM volumes significantly associated with sarcopenia, adjusted volume changes of subcompartment were compared for each group by ANCOVA. We also investigated associations of z-scores transformed from regional brain volume changes across groups by ANCOVA after adjusting for several relevant factors. ICV, age, sex, smoking, alcohol, exercise, education, HTN, heart disease, baseline brain volume, time interval from DEXA to the first MRI scan, and time interval between the baseline and follow-up MRI scans were included as variables. Multivariate linear regression analyses were conducted to compare the effects of ASM and handgrip strength on brain volume changes. The regression models included GM volume changes as the dependent variable, and baseline ASM, handgrip strength and BMI were included separately and together, along with adjustments for the aforementioned variables. A \( P \) value \(< 0.05\) was considered statistically significant.

**Statistical analyses** were performed using R version 3.5 for Windows (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Subject characteristics**

The mean age of all participants was 58.0 ± 6.0 years (range, 49 to 80), and the mean BMI was 24.5 ± 2.8 kg/m². Of the 1284 subjects, 71.2% were classified as the control group, and 12.6%, 10.8%, and 5.4% were designated as the low mass, low strength, and sarcopenia groups, respectively. The clinical characteristics of the
four strata of study subjects are listed in Table 1. Participants with sarcopenia were older and less likely to be current drinkers than the control group. The sarcopenia group did less regular exercise and had lower levels of education than the control group. The low mass and sarcopenia groups were more obese than the control group (BMI = 27.4 and 25.9, respectively, versus 24.0 kg/m², \( P < 0.001 \)), and had higher triglyceride, HOMA-IR, and hsCRP levels. The sarcopenia group reported more HTN and heart disease than the control group. The average period between the baseline and follow-up brain MRI scans was 4.2 ± 0.5 years, with no significant differences among the four groups.

Adjusted mean changes in total and regional brain volumes in groups classified by muscle mass and strength

Table 2 and Fig. 1 present the adjusted mean changes during the four years from baseline to follow-up and the z-scores in total and regional brain volumes for the four groups categorized at baseline. The atrophy rate in GM volume differed significantly among the four groups \( (P < 0.001) \). The mean adjusted difference in GM volume atrophy between the control and sarcopenia group was \(-2.12 \text{mL} (95\% \text{CI} -4.07 \text{ to } -0.17 \text{mL})\) during 4-year follow-up period. The GM volume decrease was similarly higher in the low mass, low strength, and sarcopenia groups compared with the control, and the difference

Table 1 Baseline characteristics of the study subjects

|                          | Control                      | Low mass                     | Low strength                  | Sarcopenia       | \( p \) value\(^b\) |
|--------------------------|------------------------------|------------------------------|------------------------------|-----------------|---------------------|
| \( N = 1284 \)           |                              |                              |                              |                 |                     |
| Age, y                   | 57.2 ± 5.5                  | 58.9 ± 5.5\(^c\)            | 59.7 ± 6.4\(^c\)            | 62.1 ± 7.0\(^c\) | <0.001              |
|Sex, male                | 42.0 (46)                   | 69 (42)                      | 57 (41)                      | 34 (49)         | 0.552               |
|Smoking, current          | 95 (10-4)                   | 10 (6-2)                     | 14 (10-1)                    | 5 (7-3)         | 0.404               |
|Alcohol, current          | 437 (47-8)                  | 70 (43-2)                    | 52 (37-4)                    | 21 (30-4)       | 0.005               |
|Regular exercise          | 344 (37-7)                  | 43 (26-5)                    | 40 (28-8)                    | 13 (18-8)       | <0.001              |
|Education                 |                              |                              |                              |                 |                     |
|Primary                   | 65 (7-1)                    | 21 (13-0)\(^d\)             | 21 (15-1)\(^d\)             | 10 (14-5)       |                     |
|Secondary                 | 624 (68-4)                  | 106 (65-4)\(^d\)            | 92 (66-2)\(^d\)             | 43 (62-3)       |                     |
|College/university        | 224 (24-5)                  | 35 (21-6)\(^d\)             | 26 (18-7)\(^d\)             | 16 (23-2)       |                     |
|BMI, kg/m\(^2\)          | 24.0 ± 2.5                  | 27.4 ± 2.9\(^c\)            | 23.6 ± 2.7                   | 25.9 ± 2.4\(^c\) | <0.001              |
|Waist circumference, cm   | 80.2 ± 8.0                  | 87.0 ± 8.0\(^c\)            | 79.0 ± 7.5                   | 83.9 ± 7.2\(^c\) | <0.001              |
|SBP, mm Hg                | 114.0 ± 14.0                | 116.7 ± 14.0                 | 113.5 ± 14.8                 | 116.5 ± 14.0    | 0.060               |
|DBP, mm Hg                | 74.6 ± 9.6                  | 76.8 ± 9.6\(^c\)            | 73.0 ± 9.5                   | 73.9 ± 9.2      | 0.005               |
|FPG, mmol/L               | 5.0 ± 0.4                   | 5.1 ± 0.4                    | 4.9 ± 0.4\(^c\)             | 5.0 ± 0.4       | <0.001              |
|HbA1c, mmol/mol\(^a\)    | 37 (34–39)                  | 37 (34–39)                   | 37 (33–39)                   | 37 (34–38)      | 0.442               |
|Triglycerides, mmol/L\(^a\) | 1.3 (0.9–1.7)            | 1.4 (1.1–2.0)\(^c\)       | 1.3 (1.0–1.7)                | 1.4 (1.0–1.8)   | 0.023               |
|Total cholesterol, mmol/L | 5.2 ± 0.9                   | 5.2 ± 0.9                    | 5.1 ± 0.9                    | 4.9 ± 1.0\(^c\) | 0.033               |
|HDL cholesterol, mmol/L   | 1.3 ± 0.3                   | 1.2 ± 0.3\(^c\)             | 1.3 ± 0.3                    | 1.2 ± 0.3       | 0.004               |
|HOMA-IR\(^b\)            | 1.6 (1.3–2.1)               | 2.0 (1.6–2.6)\(^c\)       | 1.5 (1.2–1.8)                | 1.7 (1.5–2.3)   | <0.001              |
|hsCRP, mmol/L\(^a\)      | 5.0 (3.0–9.0)               | 8.9 (5.3–19.7)\(^c\)      | 5.4 (3.7–10.9)               | 7.0 (3.5–12.6)  | <0.001              |
|ASMI, kg                  | 17.7 ± 4.2                  | 15.9 ± 3.7\(^c\)           | 16.1 ± 3.5\(^c\)            | 15.2 ± 3.5\(^c\) | <0.001              |
|ASM/BMI                   | 0.74 ± 0.16                 | 0.58 ± 0.16\(^c\)          | 0.69 ± 0.14\(^c\)           | 0.59 ± 0.16\(^c\) | <0.001              |
|Handgrip strength, kg\(^a\) | 29.3 (23.3–39.4)          | 26.0 (22.1–37.0)            | 18.5 (16.9–29.6)            | 18.7 (17.5–28.4) | <0.001              |
|HTN                       | 249 (27.2)                  | 57 (35-2)                    | 37 (26-6)                    | 27 (39-1)\(^d\) | 0.042               |
|Heart disease             | 38 (4)                      | 7 (4.3)                      | 8 (5.8)                      | 7 (10-1)\(^d\)  | 0.133               |
|ICV, mL                   | 1407.2 ± 133.0              | 1396.9 ± 133.0              | 1383.1 ± 138.8              | 1363.5 ± 134.5\(^c\) | 0.017               |

Data are presented as number (%), mean ± SD, or median (interquartile range)

\(^a\) Statistical significance was estimated after logarithmic transformation

\(^b\) ANOVA test of four groups and corresponding characteristics

\(^c\) Significantly different from control \( (P < 0.05) \)

Abbreviations: ASM, appendicular skeletal muscle mass; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitive C-reactive protein; HTN, hypertension; ICV, intracranial volume; SBP, systolic blood pressure
ΔLH.hippocampus − 12-7 (− 15-1, − 10-3) − 12-8 (− 16-0, − 9-7) − 14-0 (− 17-2, − 10-8) − 14-2 (− 18-2, − 10-1) 0-693
ΔRH.hippocampus − 3-7 (− 6-0, − 1-3) − 2-2 (− 5-2, 0-9) − 3-2 (− 6-4, − 0-1) − 3-9 (− 7-8, 0-1) 0-663
ΔSubcortical GM − 9-6 (− 10-9, − 8-3) − 1-6 (− 13-3, − 9-0b) − 11-6 (− 13-3, − 9-9b) − 11-6 (− 13-7, − 9-4) < 0.001
ΔInsular GM − 2-3 (− 2-9, − 1-7) − 3-3 (− 4-1, − 2-5b) − 2-8 (− 3-6, − 2-0) − 3-1 (− 4-1, − 2-1) 0-003
ΔOccipital GM − 1-6 (− 1-9, − 1-2) − 2-0 (− 2-4, − 1-5) − 2-0 (− 2-5, − 1-6) − 2-4 (− 3-0, − 1-8b) 0-002
ΔParietal GM − 0-8 (− 1-2, − 0-5) − 0-8 (− 1-3, − 0-3) − 1-4 (− 1-8, − 0-9) − 0-9 (− 1-5, − 0-3) 0-050
ΔTemporal GM − 2-0 (− 2-4, − 1-6) − 2-5 (− 3-0, − 2-0b) − 2-1 (− 2-6, − 1-7) − 2-5 (− 3-1, − 1-9) 0-016
ΔCingulate GM − 0-4 (− 0-5, − 0-2) − 0-3 (− 0-5, − 0-1) − 0-3 (− 0-5, − 0-1) − 0-4 (− 0-7, − 0-1) 0-865
ΔInsular GM − 0-08 (− 0-12, − 0-04) − 0-06 (− 0-11, − 0-01) − 0-08 (− 0-13, − 0-02) − 0-06 (− 0-13, 0-004) 0-682
ΔCerebellar GM − 1-5 (− 1-9, − 1-2) − 1-6 (− 2-0, − 1-2) − 1-7 (− 2-2, − 1-3) − 1-5 (− 2-0, − 1-0) 0-705
ΔSubcortical GM − 1-1 (− 1-2, − 1-0) − 1-1 (− 1-3, − 1-0) − 1-1 (− 1-3, − 1-0) − 0-9 (− 1-1, − 0-8) 0-151
ΔRH.hippocampus − 0.003 (− 0.02, 0.01) − 0.008 (− 0.03, 0.01) 0.012 (− 0.01, 0.03) − 0.005 (− 0.03, 0.02) 0.221
ΔLH.hippocampus − 0.017 (− 0.03, − 0.002) − 0.028 (− 0.05, − 0.01) − 0.002 (− 0.02, 0.00) − 0.014 (− 0.04, 0.01) 0.102

Data are presented as adjusted mean (95% confidence interval). Volume changes (ΔVolume) are adjusted for baseline intracranial volume, age, sex, smoking, alcohol, exercise, education, hypertension, heart disease, time between dual-energy X-ray absorptiometry and first MRI, time between MRI scans, and baseline brain volume.

Volume changes (ΔVolume) were calculated by subtracting baseline brain volumes from follow-up brain volumes.

* ANOVA test of four groups

b Significantly different from control (P < 0.05)

Abbreviations: GM gray matter; MRI magnetic resonance imaging; WM white matter; RH right hemisphere; LH left hemisphere

Fig. 1 Adjusted Z-scores of longitudinal changes in total and regional brain volumes in groups classified by muscle mass and strength. ΔVolumes are adjusted for intracranial volume, age, sex, smoking, alcohol, exercise, education, hypertension, heart disease, time between dual-energy X-ray absorptiometry and first MRI, time between MRI scans, and baseline brain volume. *, Significantly (P < 0.05) different from control. **, Significantly (P < 0.01) different from control. Abbreviations: GM, gray matter; MRI, magnetic resonance imaging; WM, white matter

was statistically significant in the low mass and low strength groups (Fig. 1). The mean annual adjusted rate of decrease in GM volume was 0.34% per year in the control group, whereas it was 0.41, 0.42, and 0.41% per year in the low mass, low strength and sarcopenia groups, respectively (P = 0.009). The reduction in total brain and WM volume did not differ significantly among the four groups.
In the lobar brain volume analyses, the change in GM volume over four years differed significantly across groups in the frontal ($P=0.003$), parietal ($P=0.002$), and occipital GM ($P=0.016$) areas (Table 2). Specifically, the low mass group showed a significantly greater decrease in the frontal and occipital GM volumes than the control group (Fig. 1). The sarcopenia group showed more prominent atrophy in the parietal GM volume than the control group (Fig. 1). The significantly greater atrophy in the parietal GM of the sarcopenia group was mostly driven by the left inferior parietal lobule (IPL) ($P=0.043$, Trend $P=0.044$, Fig. 2, Supplementary Table). Reductions in the temporal, cingulate, insular, cerebellar, and subcortical GM volumes did not differ among the four groups, nor did the groups differ significantly in volume changes of the hippocampus ($P=0.221$ for $\Delta$RH. hippocampus, $P=0.102$ for $\Delta$LH.hippocampus).

**Effects of baseline sarcopenic parameters on four-year GM volume changes**

We evaluated the effects of muscle mass and function on GM volume changes using several regression models (Table 3). Model 1 included BMI, ASM, and handgrip strength separately with other covariates and revealed that lower ASM or handgrip strength was significantly associated with faster GM reduction ($P=0.048$ for ASM, $P=0.019$ for handgrip strength). Model 2 included ASM, handgrip strength, and BMI together with other covariates and showed that low muscle mass and high BMI, not muscle strength, were significantly associated with faster GM reduction ($P=0.034$ and $0.012$). The standardized regression coefficient values for the effect of ASM and handgrip strength on GM atrophy were $0.14$ and $0.08$, respectively (Table 3).

**Fig. 2** Subregions of parietal lobe with significant atrophy associated with sarcopenia. The inferior parietal lobe in the left hemisphere showed both a significant group difference (ANOVA $P=0.043$) and a significant trend (Trend $P=0.044$) in volume change (marked in red). The inferior lobe in the right hemisphere (yellow, Trend $P=0.044$) showed a significant trend of faster atrophy between the control, low mass, and low strength groups and the sarcopenia group. The right supramarginal area, which showed significant group differences, is also marked in yellow (ANOVA $P=0.044$, see Supplementary Table 1)
### Table 3  Linear regression analyses between baseline sarcopenic parameters and GM volume changes

|       | β Estimate | Standardized β | SE | p value |
|-------|------------|----------------|----|---------|
| Model 1 | 1) BMI, kg/m² | -0.13 | 0.08 | 0.105 |
|       | 2) ASM, kg | 0.22 | 0.11 | 0.048 |
|       | 3) Handgrip strength³, kg | 2.91 | 1.24 | 0.019 |
| Model 2 | BMI, kg/m² | -0.22 | -0.08 | 0.09 | 0.012 |
|       | ASM, kg | 0.28 | 0.14 | 0.13 | 0.034 |
|       | Handgrip strength³, kg | 2.06 | 0.08 | 1.33 | 0.123 |

Model 1 evaluated the effects of BMI, ASM, and handgrip strength separately in models 1), 2), and 3), respectively. Model 2 considered BMI, ASM and handgrip strength jointly. All models were adjusted for intracranial volume, age, sex, smoking, alcohol, exercise, education, hypertension, heart disease, baseline GM volume, time between dual-energy X-ray absorptiometry and first MRI, and time between MRI scans. GM volume changes were calculated by subtracting baseline brain volumes from follow-up brain volumes

* Statistical significance was estimated after logarithmic transformation

Abbreviations: ASM appendicular skeletal muscle mass; BMI body mass index; GM gray matter; MRI magnetic resonance imaging

### Discussion

This study provides new evidence on the association between sarcopenic properties and GM atrophy in a middle-aged population. We found that low muscle mass, with or without accompanying low strength, was associated with a decrease in frontal, parietal, and occipital GM volume. The parietal lobe exhibited the highest degree of GM atrophy associated with sarcopenia, mostly driven by the left IPL. We further found that the association between muscle mass and the change in total GM volume was independent of muscle function and other covariates. To the best of our knowledge, this study is the first longitudinal study to demonstrate a relationship between parietal GM atrophy and sarcopenia, defined as reduced muscle mass and function together.

Brain volume has been observed to decline with age [20], and normal aging of the brain generally presents GM atrophy [11, 20, 21]. Among several factors affecting GM atrophy, our result provides clear evidence that it could be accelerated in individuals with low muscle mass and function. This finding is of clinical importance because GM loss has been shown to be associated with the clinical progression of dementia [22].

On the other hand, we found no significant association between muscle mass or strength and WM volume. In previous cross-sectional studies, muscle size was mainly associated with WM volume [9, 10]. Our finding could enhance the previous findings that GM volume loss starts at an earlier age and progresses more rapidly than WM volume loss [23]. A previous study reported that WM atrophy might occur in men in their 70s [11]. Another study with a longer follow-up period or with participants in their 70s and older might be required to clarify the association between sarcopenia and WM volume atrophy.

The parietal lobe, especially the left IPL, exhibited the highest degree of GM atrophy associated with sarcopenia in this study. The IPL is specifically purposed to be involved in processes relating to motor attention, planning, and movement selection [24, 25]. Our findings might thus support previous neurophysiological observations that lesions in the left hemisphere that include inferior parietal cortices often cause ideomotor apraxia [24, 26]. Moreover, GM loss in the parietal lobe has been found in the early stage of Alzheimer’s dementia and mild cognitive impairment [27], suggesting that atrophy in those areas might lead to motor and cognitive dysfunction in individuals with sarcopenia. Further research is needed to determine whether atrophy of parietal GM related to sarcopenia contributes to cognitive impairment or dementia.

Little is known about the longitudinal relationship between muscle mass and brain structural changes. We found only one follow-up study, and it concluded that a larger neck muscle cross-sectional area was associated with less whole brain atrophy [28]. Our research compared the effects of muscle mass and function on GM volume changes. In the intergroup comparison, low muscle mass and function were both associated with a greater GM volume reduction than found in the control. However, in the joint regression model, only reduced muscle mass, not muscle function, was independently associated with greater GM atrophy, and the effect size of muscle mass was also greater than that of muscle function. Although further study is required, our results suggest that muscle mass could play a greater role than muscle function in preserving GM volume with age. This is the first study to compare the effect size of muscle mass and function on future GM volume decline. Further large-scale, long-term follow-up studies that minimize the influence of muscle function or fat mass are needed to clarify the independent role of muscle mass in maintaining brain volume.
Still there has been no consensus for the gold standard criteria for sarcopenia. When evaluating the adequacy of muscle mass, the absolute ASM level has been modified to adjust for body size in different ways [29–31] because muscle mass is generally proportional to body size. Many previous studies have used ASM/height² as an indicator of sarcopenia, but it shows a positive correlation with BMI and could underestimate sarcopenia in people with a high BMI [32]. ASM/BMI was proposed by the FNIH Sarcopenia Project as a relatively new operational method for calculating muscle mass [17] that provides better prognostic values for body aging [33] and mortality [34] than ASM/height². In addition, the cutoff point for low muscle mass has varied in different studies. We used cutoffs of the lowest quintile for each component as suggested by a number of working groups [1, 35, 36], because of an extremely low prevalence of sarcopenia in Asians using other cutoffs [37], and the lack of outcome-based cutoff values for handgrip strength. For this reason, AWGS recommends using the lower 20th percentile of the study population as the cutoff value for low muscle mass or strength [35]. Furthermore, a recent study demonstrated that using the lowest quintile had better predictive values for mortality than using other criteria [34].

Several mechanisms have been suggested to explain the link between brain health and reduced muscle mass or function. One of them is the level of physical activity, which can modulate the release of various neurochemicals [38]. Structural brain changes after physical activity are assumed to be mediated by brain-derived neurotrophic factor (BDNF) [39]. Reduced serum BDNF concentrations were linked to a decline in hippocampal volume, whereas upregulated BDNF levels after exercise training increased hippocampal volume [40]. Other possible mediators include exercise-induced alterations in insulin-like growth factor-1 [41], homocysteine [42], irisin [43], vascular endothelial-derived growth factor [44], metabolites [45], and hormonal responses, which all mediate an active interaction between muscles and the brain through muscle–organ crosstalk [46]. In this study, low muscle mass or strength was associated with greater GM atrophy even after adjusting for exercise, suggesting the existence of other mechanisms associated with the muscle itself, not the effects of physical exercise.

Some limitations of this study should be noted. First, the assessment of muscle mass and brain MRI scans were not conducted at the same time. The average period between the DEXA and brain MRI studies was 2.8 ± 1.0 years. However, even after adjusting for those time differences, regional brain volumes differed significantly by group. Second, we did not consider cognitive function in this study. Future study is needed to determine whether muscle properties are linked to the cognitive function, with or without brain atrophy in adulthood.

Our study has several strengths. First, this is a four-year, longitudinal, population-based study with a large sample size and brain MRI imaging data. Second, muscle mass was measured using DEXA, which is the most standard method. Third, muscle function was evaluated together with muscle mass to define sarcopenia, and muscle mass standardized by body size (ASM/BMI) was used as the sarcopenia parameter, based on a recent guideline. These strengths allowed us to broaden our understanding of the longitudinal effects of muscle mass and function on brain atrophy more comprehensively and concisely than any previous studies.

Conclusions
Sarcopenia is associated with parietal GM volume atrophy in a middle-aged population. Large muscle mass is independently associated with the preservation of GM volume in this large, longitudinal follow-up study.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12877-021-02581-4.

Additional file 1: Supplementary Table. Adjusted means of regional volume changes in the parietal lobe according to groups classified by muscle mass and strength.

Acknowledgements
None to declare.

Authors' contributions
Ji Hee Yu, Conceptualization, Formal analysis, Writing- original draft; Regina E.Y. Kim, Methodology, Formal analysis, Software; Jin-Man Jung, Methodology, Software; So Young Park, Investigation, Data Curation; Da Young Lee, Investigation, Data Curation, Hyun Joo Cho, Formal analysis; Nam Hoon Kim, Investigation, Writing- review and editing; Hyee Jin Yoo, Visualization, Writing- review and editing; Ji A Seo, Investigation, Methodology; Sin Gon Kim, Investigation, Writing- review and editing; Kyung Moo Choi, Investigation, Writing- review and editing; Sei Hyun Baik, Conceptualization, Writing- review and editing; Chol Shin, Supervision, Project administration; Nan Hee Kim, Funding acquisition, Project administration, Supervision. All authors reviewed and approved the manuscript.

Funding
This research was supported by funds (2009-E71002–00, 2010-E71001–00, 2011-E71004–00, 2012-E71005–00, 2013-E71005–00, 2014-E71003–00, 2015-P71001–00, 2016-E71003–00, 2017-E71001–00, 2018-E7101–00) from the Korean Centers for Disease Control and Prevention, the Bio & Medical Technology Development Program of the National Research Foundation.
Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults: Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249–56. https://doi.org/10.1016/j.jamda.2011.01.003.

Arango-Lopera VE, Arroyo P, Gutiérrez-Robledo LM, Pérez-Zepeda MU, Cesari M. Mortality as an adverse outcome of sarcopenia. J Nutr Health Aging. 2013;17:259–62. https://doi.org/10.1007/s12603-012-0434-0.

Atkinson HH, Rosano C, Simmson WC, Williamson JD, Davis C, Ambrosius WT, et al. Cognitive function, gait speed decline, and comorbidities: the Aging. 2013;17:259–62. https://doi.org/10.1007/s12603-012-0434-0.

Rosano C, Keller LH, Chung H, Arnold AM, Longstreth WT Jr, Newman AB. Subcortical brain magnetic resonance imaging abnormalities predict physical functional decline in high-functioning older adults. J Am Geriatr Soc. 2005;53:649–54. https://doi.org/10.1111/j.1532-5415.2005.53214.x.

Gilbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology. 2008;71:108–13. https://doi.org/10.1212/01.wnl.000031679986917.37.

Doi T, Makizako H, Shimada H, Yoshida D, Ito K, Kato T, et al. Brain atrophy and trunk stability during dual-task walking among older adults. J Gerontol A Biol Sci Med Sci. 2012;67:790–5. https://doi.org/10.1093/gerona/glt214.

Aribisala BS, Gow AJ, Bastin ME, del Carmen Valdes Hernandez M, Murray C, Royle NA, et al. Associations between level and change in physical function and brain volumes. PLoS One. 2013;8:e80386. https://doi.org/10.1371/journal.pone.0080386.

Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol. 2010;67:428–33. https://doi.org/10.1001/archneur.2010.138.

Kilgour AH, Todd OM, Starr JM. A systematic review of the evidence that brain structure is related to muscle structure and their relationship to brain and muscle function in humans over the lifespan. BMC Geriatr. 2014;14:85. https://doi.org/10.1186/1471-2318-14-85.

Kim RE, Yun CH, Thomas RJ, Oh JH, Johnson HJ, Kim S, et al. Lifestyle-dependent brain change: a longitudinal cohort MRI study. Neurobiol Aging. 2018;69:48–57. https://doi.org/10.1016/j.neurobiolaging.2018.04.017.

Kim RE, Lourens S, Long JD, Paulsen JS, Johnson HJ. Preliminary analysis using multi-atlas labeling algorithms for tracing longitudinal change. Front Neurosci. 2015;9:242. https://doi.org/10.3389/fnins.2015.00242.

Kim EY, Johnson H. Robust multi-site MR data processing: iterative optimization of bias correction, tissue classification, and registration. 2013.7. https://doi.org/10.3389/fninf.2013.00029.

Ghavoir A, Vaidya JG, Johnson HJ. Robust automated constellation-based landmark detection in human brain imaging. Neuroimage. 2018;170:471–81. https://doi.org/10.1016/j.neuroimage.2017.04.012.

Wang H, Yushkevich PA. Multi-atlas segmentation with joint label fusion and corrective learning—an open source implementation. Front Neuroinform. 2013;7:27. https://doi.org/10.3389/fninf.2013.00027.

Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52:214–8. https://doi.org/10.1093/acidbm/52.2.214.

Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–58. https://doi.org/10.1093/gerona/glq010.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7. https://doi.org/10.2337/diacare.26.11.3160.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. https://doi.org/10.1007/BF00280883.

Raz N, Lindenberger U, Rodrigue KM, Kennedy KW, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiability. Cereb Cortex. 2005;15:1676–89. https://doi.org/10.1093/ercor/bhi044.

Driscoll I, Davatzikos C, An Y, Wu X, Shen D, Kraut M, et al. Longitudinal pattern of regional brain volume change differentiates aging normal from MCI. Neurology. 2009;72:1206–13. https://doi.org/10.1212/25WNL.0b013e3181b6e254.

Anderson VM, Schott JM, Bartlett JW, Leung KK, Miller DH, Fox NC. Gray matter atrophy rate as a marker of disease progression in AD. Neurobiol Aging. 2012;33:1194–202. https://doi.org/10.1016/j.neurobiolaging.2010.11.001.

Hedman AM, van Haren NE, Schnack HG, Kahn RS, Hulshoff Pol HE. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp. 2012;33:1985–2012. https://doi.org/10.1002/hbm.21334.

Rushworth MF, Nixon PD, Nordin SJ, Wade DT, Passingham RE. The left parietal cortex and motor attention. Neuropsychologia. 1997;35:1261–73. https://doi.org/10.1016/0028-3932(97)00050-x.

Rushworth MF, Johansen-Berg H, Gobel SM, Devlin JT. The left parietal and premotor cortices: motor attention and selection. Neuroimage. 2005;20(Suppl 1):589–5100. https://doi.org/10.1016/j.neuroimage.2003.09.011.

Buxbaum LJ, Randerath J. Limb apraxia and the left parietal lobe. Handb Clin Neurol. 2018;151:349–63. https://doi.org/10.1016/B978-0-444-63622-5.00017-6.

Jacobs H, Van Boxtel MP, Jolles J, Verhey FR, Uylings HB. Parietal cortex matters in Alzheimer’s disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev. 2012;36:297–309. https://doi.org/10.1016/j.neubiorev.2011.06.009.
28. Kilgour AH, Ferguson KJ, Gray CD, Deary IJ, Wardlaw JM, MacLullich AM, et al. Neck muscle cross-sectional area, brain volume and cognition in healthy older men: a cohort study. BMC Geriatr. 2013;13:20. https://doi.org/10.1186/1471-2318-13-20.

29. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63. https://doi.org/10.1093/oxfordjournals.aje.a009520.

30. Cawthon PM, Peters KW, Shardell MD, McLean RR, Dam TT, Kenny AM, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014;69:567–75. https://doi.org/10.1093/gerona/glu023.

31. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889–96. https://doi.org/10.1046/j.1532-5415.2002.50216.x.

32. Newman AB, Visser M, Goodpaster B, Nevitt M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51:1602–9. https://doi.org/10.1046/j.1532-5415.2003.51534.x.

33. Kim HK, Lee YJ, Lee YK, Kim H, Koo KH. Which index for muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability? J Am Geriatr Soc. 2002;50:889–96. https://doi.org/10.1046/j.1532-5415.2002.50216.x.

34. Moon JH, Kim KM, Kim JH, Moon JH, Choi SH, Lim S, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014;69:567–75. https://doi.org/10.1093/gerona/glu023.

35. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889–96. https://doi.org/10.1046/j.1532-5415.2002.50216.x.

36. Newman AB, Visser M, Goodpaster B, Nevitt M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003;51:1602–9. https://doi.org/10.1046/j.1532-5415.2003.51534.x.

37. Kim YS, Lee Y, Chung YS, Lee DJ, Joo NS, Hong D, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the fourth Korean National Health and nutritional examination surveys. J Gerontol Ser A Biol Sci Med Sci. 2012;67(A):1107–13. https://doi.org/10.1093/gerona/gli071.

38. Neufer PD, Bamman MM, Muoio DM, Bouchard C, Cooper DM, Goodpaster BH, et al. Understanding the cellular and molecular mechanisms of physical activity-induced health benefits. Cell Metab. 2015;22:4–11. https://doi.org/10.1016/j.cmet.2015.05.011.

39. Kupers S, Bramham CR. Brain-derived neurotrophic factor mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci. 2001;21:1628–34.

40. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244. https://doi.org/10.1371/journal.pone.0012244.

41. Li DJ, Li YH, Yuan HB, Qu LF, Wang P. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017;68:31–42. https://doi.org/10.1016/j.metabol.2016.12.003.

42. Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci. 2003;18:2803–12. https://doi.org/10.1111/j.1460-9568.2003.03041.x.

43. Familok M, Familok K, Tam B, Kaufer D, Baiker A, Simmons N, et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci. 2003;18:2803–12. doi:10.1111/j.1460-9568.2003.03041.x.

44. Rai M, Demontis F. Systemic nutrient and stress signaling via Myokines and Myometabolites. Annu Rev Physiol. 2016;78:85–107. https://doi.org/10.1146/annurev-physiol-021115-105305.

45. Pedersen BK. Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol. 2019;15:383–92. https://doi.org/10.1038/s41574-019-0174-x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.